Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: J Hepatol. 2015 Apr 20;63(3):670–678. doi: 10.1016/j.jhep.2015.04.013

Figure 4. Axl inhibitor BGB324 reduces HSC activation in vitro and liver fibrosis in CCl4-treated mice.

Figure 4

A, Representative western blot of α-SMA expression in cell extract from WT HSCs treated with BGB324 (0-2 μM) for 24 hours or vehicle (lanes 1 and 2) in upper image; and phospho-Axl, phospho-MERTK, and β-actin in total extracts, from LX2 cells after rGas6 administration (500 ng/ml) and BGB324 pre-incubation (30 min, 1 μM) in lower image (n=3). B, phospho-AKT, AKT and α-SMA expression in LX2 cells pre-treated with BGB324 (30 min, 1 μM) before administration of different doses of rGas6 for 30 min. (n=2). C, Hydroxyproline levels in liver extracts from WT mice treated with CCl4 or vehicle that received BGB324 (80 mg/kg, oral gavage, daily) or vehicle. D, Representative images of liver sections after Sirius Red staining (20x) from mice treated as above. E, Sirius Red quantification of liver slides. F, ALT serum levels from mice i.p. treated with CCl4 or vehicle that received Axl inhibitor or saline by oral gavage. *, P≤0.05, **, P≤0.01 vs. untreated WT mice, unless indicated. Student’s t test.